MiR-4524b-5p-targeting ALDH1A3 attenuates the proliferation and radioresistance of glioblastoma via PI3K/AKT/mTOR signaling

被引:3
|
作者
Yu, Hai [1 ,2 ]
Li, Xiaodong [1 ,2 ]
Li, Yi [3 ]
Wang, Tuo [1 ]
Wang, Maode [1 ]
Mao, Ping [1 ,2 ,4 ]
机构
[1] Xi An Jiao Tong Univ, Dept Neurosurg, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[2] Xi An Jiao Tong Univ, Ctr Brain Sci, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[3] Xi An Jiao Tong Univ, Dept Radiotherapy, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[4] Xi An Jiao Tong Univ, Dept Neurosurg, Affiliated Hosp 1, 277 West Yanta Rd, Xian 710061, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
glioblastoma; miR-4524b-5p; PI3K; AKT; mTOR signaling; radioresistance; tumor proliferation; TEMOZOLOMIDE; TARGET; RESISTANCE; CELLS;
D O I
10.1111/cns.14396
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Increasing evidence has revealed a strong connection between the aldehyde dehydrogenase family member ALDH1A3 and tumorigenesis, therapy resistance, and prognosis in diverse types of cancer. However, the specific miRNA involved in the pathways that regulate ALDH1A3-mediated glioblastoma (GBM) radioresistance remains to be elucidated. In this study, we demonstrated a high expression of ALDH1A3 in GBM cells, which plays a critical role in their proliferation and radioresistance. We also identified miR-4524b-5p, which is downregulated in GBM, as the ALDH1A3 upstream regulator. Overexpression of miR-4524b-5p reduced proliferation and radioresistance in GBM cells. Moreover, silencing ALDH1A3 reduced PI3K/AKT/mTOR signaling and glycolytic activity in GBM cells, whereas inhibiting mTOR reversed the radioresistance effects of ALDH1A3 on these cells. In vivo experiments have evidenced that ALDH1A3 silencing and miR-4524b-5p overexpression significantly reduced tumor growth and GBM cells radioresistance. In summary, targeting the miR-4524b-5p and ALDH1A3 axis is a promising therapeutic strategy for treating GBM.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
    Chang, Lei
    Graham, Peter H.
    Ni, Jie
    Hao, Jingli
    Bucci, Joseph
    Cozzi, Paul J.
    Li, Yong
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (03) : 507 - 517
  • [2] Targeting PI3K/Akt/mTOR signaling in cancer
    Porta, Camillo
    Paglino, Chiara
    Mosca, Alessandra
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [3] Punicic Acid Inhibits Glioblastoma Migration and Proliferation via the PI3K/AKT1/mTOR Signaling Pathway
    Mete, Mesut
    Unsal, Ulkun U.
    Aydemir, Isil
    Sonmez, Pinar K.
    Tuglu, Mehmet, I
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (09) : 1120 - 1131
  • [4] Targeting the PI3K/AKT/mTOR Signaling Pathway in Medulloblastoma
    Dimitrova, V.
    Arcaro, A.
    CURRENT MOLECULAR MEDICINE, 2015, 15 (01) : 82 - 93
  • [5] Tivantinib Hampers the Proliferation of Glioblastoma Cells via PI3K/Akt/Mammalian Target of Rapamycin (mTOR) Signaling
    Wu, Yukun
    Li, Zhizhang
    Zhang, Lijuan
    Liu, Guiyang
    MEDICAL SCIENCE MONITOR, 2019, 25 : 7383 - 7390
  • [6] PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
    Li, Xiaoman
    Wu, Changjing
    Chen, Nianci
    Gu, Huadi
    Yen, Allen
    Cao, Liu
    Wang, Enhua
    Wang, Liang
    ONCOTARGET, 2016, 7 (22) : 33440 - 33450
  • [7] Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma
    Bang, Jieun
    Jun, Mihyeon
    Lee, Soyun
    Moon, Hyuk
    Ro, Simon Weonsang
    PHARMACEUTICS, 2023, 15 (08)
  • [8] Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
    Li, Huayi
    Prever, Lorenzo
    Hirsch, Emilio
    Gulluni, Federico
    CANCERS, 2021, 13 (14)
  • [9] TARGETING THE PI3K/AKT/MTOR SIGNALING PATHWAYS IN CYSTIC FIBROSIS
    Reilly, R.
    Mroz, M.
    Dempsey, E.
    Shields, S.
    Wynne, K.
    McKone, E. F.
    Hiebel, C.
    Behl, C.
    Coppinger, J.
    PEDIATRIC PULMONOLOGY, 2016, 51 : 200 - 200
  • [10] miR-196b regulates gastric cancer cell proliferation and invasion via PI3K/AKT/mTOR signaling pathway
    Li, Na
    Wang, Weiqiang
    Xu, Bin
    Gong, Hongyun
    ONCOLOGY LETTERS, 2016, 11 (03) : 1745 - 1749